<DOC>
	<DOCNO>NCT01603173</DOCNO>
	<brief_summary>This randomize , open Label , two-treatment , two-period , two-sequence , crossover , single dose pivotal study . The purpose study assess bioequivalence Test Product correspond Reference Product fast condition normal , healthy , adult , human subject .</brief_summary>
	<brief_title>Bioequivalence Study Quetiapine Fumarate Tablets 25 mg Under Fasting Condition</brief_title>
	<detailed_description>Objective pivotal study assess bioequivalence Test Product : Quetiapine Fumarate Tablets 25 mg M/s Ipca Laboratories Limited , India correspond Reference Product : Seroquel® ( Quetiapine fumarate ) Tablets 25 mg M/s AstraZeneca Pharmaceuticals LP , USA , fast condition normal , healthy , adult , human subject randomize crossover study . The study conduct 54 healthy adult subject . In study period , single 25 mg dose either test reference administer subject per randomization schedule study period 240 mL water ambient temperature sit position . The duration clinical phase approximately 11 day include washout period least 7 day administration study drug study period .</detailed_description>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Male female human subject , age range 25 45 year weight ≥60 kg . 2 . BMI within range 18.5kg/m2 30 kg/m2 . 3 . Subjects normal finding determine baseline history , physical examination vital sign ( blood pressure , pulse rate , respiration rate oral temperature ) . 4 . Subjects blood pressure equal 110/70mmHg time screening time check study period . 5 . Subjects clinically acceptable finding determine haemogram , biochemistry , serology ( HIV , Hepatitis B Hepatitis C ) , urinalysis , 12 lead ECG chest Xray ( chest Xray require ) . 6 . Willingness follow protocol requirement evidence write informed consent . 7 . Confirming agree , use prescription counter medication include vitamin mineral 14 day prior study course study . 8 . No history drug abuse past one year . 9 . Nonsmokers nonalcoholics . 10 . For female subject child bear potential practicing acceptable method birth control duration study judge Investigator Condom , Foams , Jellies , Diaphragm , Intrauterine device Abstinence . OR surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy perform subject ) . 1 . Known history hypersensitivity Quetiapine , related drug . 2 . Requiring medication ailment enzymemodifying activity previous 28 day , prior dose day . 3 . Any medical surgical condition , might significantly interfere function gastrointestinal tract , bloodforming organ etc . 4 . History cardiovascular , renal , hepatic , ophthalmic , pulmonary , neurological , metabolic , hematological , gastrointestinal , endocrine , immunological psychiatric disease bleed tendency . 5 . Participation clinical drug study bioequivalence study within 90 day prior present study . 6 . History malignancy serious disease . 7 . Refusal abstain food least ten ( 10.00 ) hour prior study drug administration least four ( 04.00 ) hour postdose , study period . 8 . Any contraindication blood sample difficulty accessibility vein . 9 . Refusal abstain fluid least 01.00 hour prior study drug administration least 01.00 additional hour postdose , study period except 240 mL water give administration study drug . 10 . Refusal avoid use xanthinecontaining food beverage ( chocolate , tea , coffee cola drink ) fruit juice/grapefruit juice alcoholic product 48.00 hour prior dose last blood sample collection last study period . 11 . Blood donation within 90 day prior commencement study . 12 . Subjects positive HIV test HepatitisB HepatitisC test . 13 . Found positive breath alcohol test do checkin study period . 14 . Found positive urine test drug abuse do checkin study period . 15 . Refusal abstain consumption tobacco product 24.00 hour prior dose last blood sample collection last study period . 16 . History problem swallow Tablet ( ) . 17 . Female subject , demonstrate positive urine pregnancy test time screen . 18 . Female subject , demonstrate positive Serum ( ß ) Beta hCG ( Human Chorionic Gonadotropin ) test checkin study period . 19 . Female subject , currently breast feed lactate . 20 . Female subject willing use acceptable method contraception date screen completion study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>